Ropivacaine
| Evidence Level: L3 | Predicted Indications: 4 |
Table of Contents
Ropivacaine: From Local Anesthesia to Migraine Disorder
One-Sentence Summary
Ropivacaine is a long-acting amide local anesthetic. The data compiled for this report do not include its approved indication text. The TxGNN model predicts it may be effective for migraine disorder, with 2 clinical trials and 3 publications currently supporting this direction. The evidence is small and mostly observational, so this is best treated as a research question rather than an established use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the compiled data (all license records have empty indication text) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 8 (all ANDA generic applications, all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the compiled data. Based on known pharmacology, ropivacaine is a long-acting amide local anesthetic that blocks voltage-gated sodium channels.
Its use is regional nerve blockade. Blocking pain signaling at the sphenopalatine ganglion, stellate ganglion, occipital or trigeminal branches, or myofascial trigger points could plausibly reduce trigeminovascular activation and peripheral and central sensitization in migraine. This is a local nerve-block effect, not a systemic disease-modifying effect.
The other predictions for this drug are weak:
- Migraine with brainstem aura (score 99.55%): no trial or literature specific to this subtype. The score probably reflects similarity to general migraine.
- Nephrogenic syndrome of inappropriate antidiuresis (99.41%): this condition arises from gain-of-function mutations in the vasopressin V2 receptor. There is no plausible link to sodium-channel blockade, so it looks like a graph artifact.
- Dysthymic disorder (99.15%): no mechanistic or clinical support. Systemic exposure carries cardiotoxicity and CNS toxicity risks, which argues against chronic systemic use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03666663 | Phase 4 | Completed | 10 | Randomized, double-blind, placebo-controlled sphenopalatine ganglion block with nasal anesthetics for migraine prevention in adults. Very small, so underpowered. Ropivacaine’s role as the specific comparator should be confirmed. No results provided. |
| NCT00680823 | N/A | Completed | 150 | Paraspinal intramuscular ropivacaine injection for headache in a pediatric emergency department. Headache may not be strictly migraine. No results provided. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17244105 | 2007 | Clinical study (cohort) | Pain Med | Ropivacaine trigger point injections evaluated for migraine prophylaxis over 12 weeks in patients with severe migraine |
| 35331152 | 2022 | Observational cohort | BMC Anesthesiol | Ultrasound-guided stellate ganglion block assessed for migraine pain relief and quality of life |
| 24284858 | 2013 | Technique description / case series | Pain Physician | Revised transnasal topical sphenopalatine ganglion block for headache and facial pain |
US Market Information
All 8 records below are cancelled generic applications (single-ingredient injections). The data compiled for this report contain no approved indication text for any of them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA211907 | Ropivacaine Hydrochloride (Hikma) | Injection, solution | Not available |
| ANDA214074 | Ropivacaine Hydrochloride (Hikma) | Injection | Not available |
| ANDA212808 | Ropivacaine Hydrochloride (Caplin Steriles) | Injection | Not available |
| ANDA206091 | Ropivacaine Hydrochloride (Mylan Institutional) | Injection, solution | Not available |
| ANDA219883 | Ropivacaine Hydrochloride (Glenmark) | Injection, solution | Not available |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for label safety information.
- Contraindication signals from the knowledge graph (not label text): chronic obstructive pulmonary disease, respiratory failure, asthma, kidney disease, liver disease, biliary tract disease and obstructive jaundice, cardiovascular and heart disease, cor pulmonale, myasthenia gravis and other neuromuscular junction disease, butyrylcholinesterase deficiency, intestinal obstruction and paralytic ileus, inflammatory bowel disease, benign prostatic hyperplasia, urethral stricture, intracranial hypertension, and substance abuse or dependence. These are model-derived associations and need verification against the label.
- Drug interactions: 64 interactions were recorded, and 20 are listed in the data. Moderate-level ones include obeticholic acid, liposomal morphine, deferasirox, and fostamatinib. The rest are Minor or Unknown, such as cimetidine, clarithromycin, epinephrine, and heparin.
- Systemic toxicity: systemic exposure carries cardiotoxicity and CNS toxicity risks.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine signal is plausible mechanistically and has some supporting studies. However, the evidence is small and mostly observational (L3), and the only randomized trial enrolled 10 patients. All US licenses are cancelled, and label safety data are missing, which blocks safety screening.
To proceed, the following is needed:
- Retrieve and review the FDA package insert (warnings, contraindications, approved indications).
- Obtain detailed mechanism-of-action data from DrugBank.
- Obtain results from NCT03666663 and NCT00680823, and confirm ropivacaine’s role in the former.
- Run adequately powered randomized, controlled trials of ropivacaine nerve blocks (SPG, occipital, or trigger point) specifically in migraine.
- Confirm route compatibility and the current US regulatory pathway, given that all licenses are cancelled.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.